ClinicalTrials.gg
RecruitingNCT07470073Updated Mar 13, 2026

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

An Early Phase 1 interventional study of CT1190B cell injection in ALL (Acute B-Lymphoblastic Leukemia), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
171st of 209
18 · median 45
Started
2026
with 16 others
Phase 1
66 of 232
31 open now
Primary completion
2027-12
later than 88 of 124 live
Registered
217th of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 171st largest by planned enrollment of the 209 interventional ones that give a count, is one of 17 that started in 2026, is one of 66 in phase 1, reaches primary completion later than 88 of the 124 other live ones, and was the 217th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic leukemia.

Read the detailed description

The study was divided into dose escalation phase and dose expansion phase. It is planned to enroll 18-36 study participants.

The participants were divided into two treatment groups. Group A was adult participants ≥ 18 years old who received ct1190b treatment. The dose escalation was tentatively determined at three dose levels: dl1:3.0 × 10\^8, dl2:4.5 × 10\^8, dl3:6.0 × 10\^8 car-t cells. , Group B consisted of 12-17-year-old adolescents and children. The dose escalation was tentatively defined as two dose levels. Dl1:3.0 × 10\^6 /kg car-t cells, the maximum total number of infused cells was not more than 1.5 × 10\^8 car-t cells, dl2:6.0 × 10\^6 /kg car-t cells, the maximum total number of infused cells was not more than 3.0 × 10\^8 car-t cells. The dose escalation of the two groups followed the "i3+3" design. It was planned to enroll 18-36 study participants. At the dose escalation stage, all patients of different subtypes were mixed into the group. Without distinguishing between groups, the dose escalation of group A was given priority. After obtaining certain data, the dose escalation of group B was performed (fig.it can receive other research data of the same indication of this product). If the starting dose of group A (3.0 × 10\^8) meets the dose reduction standard according to the i3+3 principle (the i3+3 decision table indicates "d" or "Du", refer to the incremental decision table of the i3+3 principle for details), the investigator and the funder will jointly discuss and decide whether to enter the decreasing dose of 1.5 × 10\^8. If the maximum dose currently set is not confirmed as the possible recommended dose (RD), the investigator and the funder can jointly decide whether to increase it to a higher dose to explore the possible recommended therapeutic dose. During the study, the dose group may be increased or decreased or the dose may be extended according to the safety, effectiveness and cellular metabolic dynamics data of the study participants.

03

Conditions studied

  • ALL (Acute B-Lymphoblastic Leukemia)

Keywords

  • ALL (Acute B-Lymphoblastic Leukemia)
  • CT1190B
  • CAR-T
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • voluntarily participate in clinical research; I fully understand and know this study and sign the form; ;
  • aged 12-75 years (inclusive);
  • B-ALL diagnosed by morphology, immunology or molecular science, and meeting one of the following conditions:

    1. The patients who did not achieve complete remission by the standardized induction chemotherapy, or early relapse (\<12 months) after complete remission, or late relapse (≥ 12 months) after complete remission, and did not achieve complete remission by the standardized one course induction chemotherapy (except for the patients with late relapse who did not have a better treatment or did not tolerate other treatments according to the investigator's assessment), relapsed after 2 or more CR or CRI;
    2. For ph+all patients, in addition to receiving standard induction chemotherapy, they should also receive at least two kinds of TKI treatment without complete remission or relapse after complete remission (except those who cannot tolerate TKI treatment or have to TKI treatment, or those with T315I mutation do not need to receive TKI treatment);
  • CD19 and / or CD20 positive in bone marrow or peripheral blood;
  • the proportion of bone marrow cell morphology or peripheral blood suggestive blasts ≥ 5%;
  • estimated survival >12 weeks;
  • study participants should meet the following inspection results (there should be no ongoing continuous supportive care):

    1. Endogenous ≥ 30 ml/min (using Cockcroft Gault formula);
    2. (ALT) and aspartate aminotransferase (AST) ≤ 3 × , total ≤ 1.5 × ULN; In case of hepatobiliary invasion: AST and alt ≤ 5 × ULN, total bilirubin ≤ 3.0 × ULN;
    3. (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
    4. Oxygen saturation in non oxygen inhalation state was > 91%;
    5. (LVEF) ≥ 50%.
  • Male study participants who had active sex with women with were willing to use very effective and reliable methods of within 1 year after receiving study treatment. All male study participants were absolutely forbidden to donate sperm within 1 year after receiving study treatment infusion during the study period.

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating women;
  • there is , syphilis infection, active virus infection (HBV-DNA is higher than the detection limit), or active virus infection (both HCV antibody and HCV-RNA are positive);
  • there is currently any uncontrollable active infection, including but not limited to patients with active tuberculosis (judged by the investigator);
  • there is active systemic disease;
  • patients with solitary extramedullary lesions;
  • research participants with a history of neurological diseases, such as epilepsy, intracranial hemorrhage, severe brain injury, cerebellar disease, memory impairment, spinal cord compression or any disease involving the central nervous system, or suspected active central nervous system (CNS) ;
  • patients with bone marrow failure status related genetic syndromes: such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down syndrome were not excluded.
  • for patients who after treatment with drugs targeting CD19 and / or CD20 before screening, the investigator judged that they could not benefit; 10. have received stem cell transplantation within 12 weeks before signing the ; Received donor lymphocyte infusion (DLI) within 6 weeks;
  • received the following treatments before cell infusion:

    1. Received anthracyclines, vinblastines, 6-mercaptopurine, 6-thioguanine, methotrexate, cytarabine, asparaginase, etc. within 7 days before infusion;
    2. Hydroxyurea and tyrosine kinase inhibitors were used within 3 days before infusion;
    3. Radiotherapy was used within 1 week before infusion (2 weeks interval for lung radiotherapy and 8 weeks interval for CNS radiotherapy);
    4. CNS prophylactic therapy (such as intrathecal injection of chemotherapeutic drugs) within 1 week before infusion;
    5. Give any T-cell lysis or antibody (such as alemtuzumab) within 8 weeks before infusion;
    6. Use monoclonal antibody, double antibody or ADC within 4 weeks before infusion;
    7. ;
    8. Received systemic equivalent to >15 mg/ day prednisone within 3 days before infusion, except for glucocorticoids used locally;
    9. Polyethylene glycol asparaginase was used within 4 weeks before infusion;
  • have been vaccinated with , inactivated vaccine or RNA vaccine within 4 weeks before signing the informed consent;
  • those who are allergic or intolerant to Qinglin drugs and tocilizumab, or allergic to components (dimethyl sulfoxide /dmso) in ct1190b cell infusion preparations; Or previous history of other serious allergies such as anaphylactic shock;
  • patients with any of the following cardiac diseases before screening:

    1. (NYHA) class III or IV heart failure;
    2. ;
    3. A history of uncontrolled arrhythmias, such as ventricular arrhythmias;
    4. A history of severe non ischemic cardiomyopathy;
    5. Other heart diseases that the investigator believes may endanger the health of the patient due to participation in this clinical study;
  • serious lung disease may endanger the patient's life after participating in the study as judged by the investigator;
  • there are second primary malignant tumors that need treatment or have not been completely relieved in the past 2 years, except the following successfully treated tumors with low such as non metastatic basal cell carcinoma or squamous cell skin carcinoma, non metastatic prostate cancer, breast cancer or cervical cancer in situ, non muscle invasive bladder cancer or thyroid cancer;
  • major surgery within 2 weeks before signing the informed consent, or major surgery planned during the study or within 4 weeks after giving the study treatment (excluding cataract and other local anesthesia surgery);
  • after organ transplantation;
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    CT1190B CAR-T cells Injection

    The study drug was ct1190b car T-cell injection, and the car-cd19/cd20 gene was site integrated into T-cells by using replicable lentivirus (RCL) and adeno-associated virus (AAV) gene editing technology.

    Biological: CT1190B cell injection

Interventions

  • BiologicalCT1190B cell injection

    The active ingredient of the drug in this study is the chimeric antigen receptor targeting cd19/cd20 (car-cd19/cd20 for short) modified allogeneic T cells. In order to reduce the rejection of GVHD and host immune cells, TCR and B2M were knocked out, and the related modifications were also carried out to reduce the host NK cell immune rejection.

    Also known as: CT1190B

06

What researchers measure

Primary outcomes

  1. The number and severity of dose-limiting toxicity (DLT)events

    DLT was collected to explore the maximum tolerated dose (MTD) and / or dose range of CT1190B

    Time frame: Within 28 days after cell infusion

  2. Frequency, type and severity of AES

    The frequency, type and severity of adverse events (AES) were collected. All adverse events will be evaluated according to the common terminology criteria for adverse events (CTCAE, version 5.0).

    Time frame: Within 12 months after cell infusion

Secondary outcomes

  1. Investigator assessed objective response rate (ORR)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  2. Investigator assessed complete response rate (CRR)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  3. Investigator assessed proportion of minimal residual disease negative (MRD)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  4. Investigator assessed duration of remission (DOR)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  5. Investigator assessed time to remission (TTR)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  6. Investigator assessed time to complete remission (TTCR)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  7. Investigator assessed • event free survival (EFS)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  8. Overall survival (OS)

    Time frame: The evaluation was performed within 12 months after cell infusion, such as 4 weeks, 8 weeks, 12 weeks, 4 months, 6 months, 9 months, 12 months after cell infusion

  9. The level of CT1190B gene copy number

    Cell metabolic dynamics analysis will be carried out according to different treatment groups. According to the actual blood collection time, individual ct1190b cell copy number time curves (linear and semi logarithmic) were drawn. According to the blood collection time, the average and median ct1190b cell copy number time curves (linear and semi logarithmic) were drawn.

    Time frame: Day 0 before cell infusion, Day 1, Day 3, Day 7, Day 10, Day 14, Day 18 (optional), Week 3, Week 4, Week 8, Month 4 and Month 6 after cell infusion

  10. Duration of CT1190B gene copy number

    Cell metabolic dynamics analysis will be carried out according to different treatment groups. According to the actual blood collection time, individual ct1190b cell copy number time curves (linear and semi logarithmic) were drawn. According to the blood collection time, the average and median ct1190b cell copy number time curves (linear and semi logarithmic) were drawn.

    Time frame: Day 0 before cell infusion, Day 1, Day 3, Day 7, Day 10, Day 14, Day 18 (optional), Week 3, Week 4, Week 8, Month 4 and Month 6 after cell infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 20 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07470073
Responsible party
MEI HENG (Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Mar 13, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Mar 13, 2026

Study contacts

Heng Mei, M.D., Ph.D
Contact
hmei@hust.edu.cn
07596503286

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion